65 completed. 33 Phase 3, 23 Phase 2, 4 Phase 4, 2 Phase 1.
By phase and status
Follow Infections, Meningococcal: new trials by email Literature Review of Infections, Meningococcal trials Research Report on Infections, Meningococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants
MenACWY-7B low dose vaccine, MenACWY-7B high dose vaccine, MenABCWY-1Gen vaccine - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 726 | 2021-11-29 | 2026-06-26 |
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 945 | 2020-08-25 | 2025-03-04 |
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 3657 | 2020-08-14 | 2024-03-05 |
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A), Licensed GSK MenACWY vaccine (Menveo) - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 996 | 2018-09-07 | 2021-02-09 |
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1196 | 2018-07-27 | 2026-08-20 |
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 704 | 2016-12-08 | 2019-11-25 |
Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents
Meningococcal ABCWY Vaccine, Meningococcal B Recombinant vaccine - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 604 | 2016-11-15 | 2019-08-20 |
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R, Investigational MenC-CRM adjuavnted with 25 ug of LHD153R, Investigational MenC-CRM adjuavnted with 50 ug of LHD153R - Infections, Meningococcal | Phase 1 | Completed | GlaxoSmithKline | 80 | 2016-03-01 | 2019-06-28 |
Safety of 4CMenB Exposure During Pregnancy
4CMenB - Infections, Meningococcal | | Completed | GlaxoSmithKline | 2 | 2016-01-31 | 2020-09-03 |
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine) - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 531 | 2015-11-17 | 2018-11-08 |
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
MenACWY - Infections, Meningococcal | Phase 4 | Completed | GlaxoSmithKline | 128 | 2015-07-13 | 2019-06-27 |
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
MenABCWY+OMV vaccine - Meningococcal Disease, Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 129 | 2015-06-30 | 2020-07-09 |
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
Meningococcal quadrivalent CRM-197 conjugate vaccine - Meningococcal Disease, Infections, Meningococcal | | Completed | GlaxoSmithKline | 144 | 2014-12-01 | 2019-10-21 |
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Meningococcal quadrivalent CRM-197 conjugate vaccine - Meningococcal Disease, Pregnancy | | Completed | GlaxoSmithKline | 93 | 2014-09-30 | 2019-06-21 |
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Bexsero®, Routine vaccines - Meningococcal Disease, Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 225 | 2014-09-11 | 2020-08-25 |
Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
Bexsero, Saline Placebo, Havrix - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1063 | 2014-08-21 | 2019-06-27 |
Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
Meningococcal group B Vaccine, rMenB+OMV NZ, Meningococcal ACWY Conjugate Vaccine, MenACWY - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 750 | 2014-06-05 | 2018-08-22 |
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
Meningococcal vaccine GSK134612 - Infections, Meningococcal | Phase 3 | Completed | Pfizer | 311 | 2014-04-01 | 2019-08-28 |
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
Meningococcal vaccine GSK134612, Prevenar 13™ - Infections, Meningococcal | Phase 3 | Completed | Pfizer | 803 | 2013-10-02 | 2021-10-05 |
Showing 20 of 65. Sign in to see all of them.
Narrower conditions
Meningococcal Infections (65) · Meningitis (10) · Meningitis, Meningococcal (4) · Tetanus (4) · Whooping Cough (4) · Central Nervous System Diseases (2) · Diphtheria (2) · Haemophilus Infections (2) · Hepatitis B (2) · Nervous System Diseases (2)
Broader conditions
Bacterial Infections (65) · Bacterial Infections and Mycoses (65) · Gram-Negative Bacterial Infections (65) · Infections (65) · Neisseriaceae Infections (65) · Neuroinflammatory Diseases (12) · Nervous System Diseases (10) · Bordetella Infections (4) · Central Nervous System Bacterial Infections (4) · Central Nervous System Diseases (4) · Central Nervous System Infections (4) · Clostridium Infections (4) · Gram-Positive Bacterial Infections (4) · Meningitis, Bacterial (4) · Respiratory Tract Diseases (4)
Interventions
Meningococcal Vaccines (11) · 4CMenB vaccine (10) · Vaccines (5) · PsACWY vaccine (4) · Blood Specimen Collection (3) · Hiberix (3) · MenACWY (3) · Saline Solution (3) · tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (3) · Boostrix (2) · PEDIARIX (2) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · 13-valent pneumococcal vaccine (1) · Chickenpox Vaccine (1) · Data Collection (1)
Sponsors
GlaxoSmithKline (60) · Pfizer (4) · Epicentre (1)
Countries
United States (17) · Finland (10) · Philippines (10) · Germany (9) · Australia (6) · Canada (5) · Lebanon (5) · Belgium (4) · Poland (4) · Austria (3) · Czechia (3) · Denmark (3) · Dominican Republic (3) · Estonia (3) · India (3)
Top investigators
Dominique A Caugant, PhD (1) · Philippe J Guerin, MD, MPH, PhD (1)
Results publications
PMID 17287313, PMID 17065257, PMID 19048025, PMID 21343698, PMID 23510357, PMID 24567843, PMID 25152325, PMID 25305567, PMID 26237742, PMID 26398741, PMID 26437712, PMID 29789243, PMID 29960800, PMID 30691980, PMID 31116180, PMID 31669193, PMID 32284274, PMID 32552685, PMID 32598244, PMID 36369456, PMID 36564274, PMID 36621408, PMID 39647494, PMID 41276263
NIH funding
2016 (6), 2014 (3), 2017 (2), 2008 (1), 2009 (1), 2019 (1), 2023 (1)